Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma

Qiao, Peipei; Tian, Kai-Sai; Han, Lei; Ma, Ben; Shen, Chunying; Zhao, Runyu; Zhang, Yi; Wei, Wenjun; Chen, Xiaoping

doi:10.1007/s12020-022-03031-w

Cited by 6 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These preliminary results suggested that anti-PD-L1 antibody treatment could be effective in patients with MSI PDAC. MSI was reported in approximately 10–15% of thyroid carcinomas (TC) [ 175 , 176 , 177 ]; moreover, a correlation between MSI and clinical-pathological features was observed. Particularly, MSI TCs were generally papillary or anaplastic and poorly differentiated histotypes.…”

Section: Msi In Other Malignanciesmentioning

confidence: 99%

“…Particularly, MSI TCs were generally papillary or anaplastic and poorly differentiated histotypes. A recent study showed that MSI TC patients have a good prognosis compared to MSS TC [ 177 ]. Although several clinical trials are being evaluated for the efficacy of pembrolizumab, nivolumab and atezolizumab in MSI TC, until now no immunological therapy has been approved for MSI TC [ 178 , 179 ].…”

Section: Msi In Other Malignanciesmentioning

confidence: 99%

“…Although several clinical trials are being evaluated for the efficacy of pembrolizumab, nivolumab and atezolizumab in MSI TC, until now no immunological therapy has been approved for MSI TC [ 178 , 179 ]. The ICI targeting the PD-1/PD-L1 pathway may be a treatment option for MSI TC; however, further studies are needed [ 177 ]. The frequency of MSI brain tumors is very low, ranging from 2% to 3% of cases [ 27 , 116 ].…”

Section: Msi In Other Malignanciesmentioning

confidence: 99%

See 2 more Smart Citations

Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers

Amato

Franco

Facchini

et al. 2022

IJMS

View full text Add to dashboard Cite

Microsatellite instability (MSI) has been identified in several tumors arising from either germline or somatic aberration. The presence of MSI in cancer predicts the sensitivity to immune checkpoint inhibitors (ICIs), particularly PD1/PD-L1 inhibitors. To date, the predictive role of MSI is currently used in the selection of colorectal cancer patients for immunotherapy; moreover, the expansion of clinical trials into other cancer types may elucidate the predictive value of MSI for non-colorectal tumors. In clinical practice, several assays are used for MSI testing, including immunohistochemistry (IHC), polymerase chain reaction (PCR) and next-generation sequencing (NGS). In this review, we provide an overview of MSI in various cancer types, highlighting its potential predictive/prognostic role and the clinical trials performed. Finally, we focus on the comparison data between the different assays used to detect MSI in clinical practice.

show abstract

Section: Msi In Other Malignanciesmentioning

confidence: 99%

Section: Msi In Other Malignanciesmentioning

confidence: 99%